Sam Brusco, Associate Editor03.02.22
Active healing company Bioventus has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the next generation of its StimRouter neuromodulation system to treat chronic pain arising from peripheral nerves (excluding craniofacial). The minimally invasive device consists of a thin, implanted lead with conductive electrode, external electric field conductor (E-EFC), and StimRouter Plus mobile app. The E-EFC transcutaneously send electrical signals, conducted to the target nerve via the lead.
The next-gen StimRouter improves on the previous generation via the new smartphone app and new E-ERC.
“The impact of chronic, debilitating pain is more than just managing the impacted anatomy, it is also about helping return the individual back to a life pre-pain,” said John Nosenzo, chief commercial officer of Bioventus told the press. “The emotional and psychological damage from living with pain is horrific and we are pleased to support all the physicians who are committed to improving patient lives, in particular with alternatives to opioids when possible. The next generation StimRouter will support patients and physicians to meet their pain treatment goals as the previous generation of peripheral nerve stimulation has done for many years.”
Over 50 million Americans currently live with chronic pain. Peripheral nerve stimulation (PNS) offers a focal, non-opioid treatment for the debilitating pain.
The next-gen StimRouter improves on the previous generation via the new smartphone app and new E-ERC.
“The impact of chronic, debilitating pain is more than just managing the impacted anatomy, it is also about helping return the individual back to a life pre-pain,” said John Nosenzo, chief commercial officer of Bioventus told the press. “The emotional and psychological damage from living with pain is horrific and we are pleased to support all the physicians who are committed to improving patient lives, in particular with alternatives to opioids when possible. The next generation StimRouter will support patients and physicians to meet their pain treatment goals as the previous generation of peripheral nerve stimulation has done for many years.”
Over 50 million Americans currently live with chronic pain. Peripheral nerve stimulation (PNS) offers a focal, non-opioid treatment for the debilitating pain.